While the mpox emergency declaration ended as of January 31, 2023, recent data from CDC outlines low mpox vaccination rates among those at highest risk—37% for the first dose and 23% for the two dose regimen—and wide variations across jurisdictions.
Data highlights in the study, JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox — United States, May 22, 2022–January 31, 2023 (MMWR, 3/31/23), include:
- About 30,000 mpox cases were reported in 2022.
- The average number of cases reported daily plummeted, from 400 at the height in August 2022 to 5 as of January 31, 2023. Nonetheless, mpox vaccination is still recommended for those at risk, including gay, bisexual, transgender, and other persons with risky sexual encounters.
- Unvaccinated persons are 7-14 times more likely to acquire mpox compared to those having received a JYNNEOS vaccine.
- Over 1 million JYNNEOS doses were administered from May 2022 through January 2023.
- Jurisdiction variations in receipt of the first dose of JYNNEOS by at risk persons ranged from 7.4% to 94.8%.
Browse for More
Clinical Quality Management, Ending the HIV Epidemic Initiative, Health Coverage, Key Populations, Black/African American, Hispanic/Latino, Adolescents & Youth, MSM - Men who have Sex with Men, Transgender People, Medical & Support Services, Case Management, Health Literacy, Sexually Transmitted Infections, Outpatient Medical Care, People with HIV & Community Involvement, Ryan White HIV/AIDS Program & Parts